Blog

  • Harry Brook Becomes World’s Best Test Batter as Gill, Mulder, and Sri Lanka Stars Climb Rankings

    Harry Brook Becomes World’s Best Test Batter as Gill, Mulder, and Sri Lanka Stars Climb Rankings

    Harry Brook, an England cricket player, has just become the No. 1 Test batter in the world, overtaking his English teammate Joe Root, according to the International Cricket Council (ICC) rankings. 

    This exciting shift comes alongside big performances from India’s Shubman Gill, South Africa’s Wiaan Mulder, and Sri Lanka’s Kusal Mendis and Charith Asalanka, who are also making waves in cricket’s global rankings.

    Harry Brook’s Big Win

    Brook, the 26 year old right handed batsman,, scored 158 runs in a Test match at Edgbaston. His big score helped England stay strong in the game and pushed him to the top of the Test batting rankings, 18 points ahead of Joe Root, who’s now No. 2. Brook’s success shows he’s great at staying focused in the long, tough Test format. Other top batters include New Zealand’s Kane Williamson (No. 3), India’s Yashasvi Jaiswal (No. 4), and Australia’s Steven Smith (No. 5).

    Shubman Gill’s Amazing Performance

    India’s Test team captain, Shubman Gill, had a huge moment in a match against England. He scored 269 runs in one innings and 161 in another, helping India win by a massive 336 runs. Gill’s performance jumped him 15 spots to No. 6 in the Test batting rankings, with a personal best 807 rating points. 

    Jamie Smith to the Rescue

    England’s Jamie Smith, the wicketkeeper batsman, also had a great game at Edgbaston. When England were in trouble, losing 5 players for just 84 runs, Smith stepped up. He scored an unbeaten 184 runs and added 88 runs in the second innings. These efforts lifted him 16 places to No. 10 in the Test batting rankings. 

    Wiaan Mulder’s Record Breaking Day

    South Africa’s Wiaan Mulder scored 367 runs without getting out in a Test against Zimbabwe. That’s one of the biggest scores ever in a single innings.
    It sent him soaring 34 spots to No. 22 in the Test batting rankings. Mulder, an allrounder, has also climbed 12 spots to No. 3 in the allrounder rankings, behind only India’s Ravindra Jadeja at No. 1.  and Mehidy Hasan Miraz (Bangladesh) at No. 2 with 305 rating points.


    Sri Lanka’s ODI Stars

    In ODIs format, Sri Lanka’s players shone in a series against Bangladesh. Kusal Mendis scored 225 runs, including a big 124 and a solid 56, earning him the Player of the Series award. This pushed him 10 spots into the top ten ODI batting rankings. 

    Sri Lanka’s captain, Charith Asalanka, scored 106 and 58 in two games, helping his team win 2-1 and moving him two spots to No. 6 in the ODI rankings. Their performances show Sri Lanka’s strength in the faster-paced ODI format.

    Why This Matters

    The ICC rankings are like a leaderboard, showing who’s hot in cricket right now. A single big game can change everything. More cricket matches are around the corner, and these rankings could change again. Brook’s at the top now, but Gill, Smith, Mulder, Mendis, and Asalanka are showing they’re ready to compete.

     

    Continue Reading

  • AI shapes autonomous underwater “gliders” | MIT News

    AI shapes autonomous underwater “gliders” | MIT News

    Marine scientists have long marveled at how animals like fish and seals swim so efficiently despite having different shapes. Their bodies are optimized for efficient, hydrodynamic aquatic navigation so they can exert minimal energy when traveling long distances.

    Autonomous vehicles can drift through the ocean in a similar way, collecting data about vast underwater environments. However, the shapes of these gliding machines are less diverse than what we find in marine life — go-to designs often resemble tubes or torpedoes, since they’re fairly hydrodynamic as well. Plus, testing new builds requires lots of real-world trial-and-error.

    Researchers from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and the University of Wisconsin at Madison propose that AI could help us explore uncharted glider designs more conveniently. Their method uses machine learning to test different 3D designs in a physics simulator, then molds them into more hydrodynamic shapes. The resulting model can be fabricated via a 3D printer using significantly less energy than hand-made ones.

    The MIT scientists say that this design pipeline could create new, more efficient machines that help oceanographers measure water temperature and salt levels, gather more detailed insights about currents, and monitor the impacts of climate change. The team demonstrated this potential by producing two gliders roughly the size of a boogie board: a two-winged machine resembling an airplane, and a unique, four-winged object resembling a flat fish with four fins.

    Peter Yichen Chen, MIT CSAIL postdoc and co-lead researcher on the project, notes that these designs are just a few of the novel shapes his team’s approach can generate. “We’ve developed a semi-automated process that can help us test unconventional designs that would be very taxing for humans to design,” he says. “This level of shape diversity hasn’t been explored previously, so most of these designs haven’t been tested in the real world.”

    But how did AI come up with these ideas in the first place? First, the researchers found 3D models of over 20 conventional sea exploration shapes, such as submarines, whales, manta rays, and sharks. Then, they enclosed these models in “deformation cages” that map out different articulation points that the researchers pulled around to create new shapes.

    The CSAIL-led team built a dataset of conventional and deformed shapes before simulating how they would perform at different “angles-of-attack” — the direction a vessel will tilt as it glides through the water. For example, a swimmer may want to dive at a -30 degree angle to retrieve an item from a pool.

    These diverse shapes and angles of attack were then used as inputs for a neural network that essentially anticipates how efficiently a glider shape will perform at particular angles and optimizes it as needed.

    Giving gliding robots a lift

    The team’s neural network simulates how a particular glider would react to underwater physics, aiming to capture how it moves forward and the force that drags against it. The goal: find the best lift-to-drag ratio, representing how much the glider is being held up compared to how much it’s being held back. The higher the ratio, the more efficiently the vehicle travels; the lower it is, the more the glider will slow down during its voyage.

    Lift-to-drag ratios are key for flying planes: At takeoff, you want to maximize lift to ensure it can glide well against wind currents, and when landing, you need sufficient force to drag it to a full stop.

    Niklas Hagemann, an MIT graduate student in architecture and CSAIL affiliate, notes that this ratio is just as useful if you want a similar gliding motion in the ocean.

    “Our pipeline modifies glider shapes to find the best lift-to-drag ratio, optimizing its performance underwater,” says Hagemann, who is also a co-lead author on a paper that was presented at the International Conference on Robotics and Automation in June. “You can then export the top-performing designs so they can be 3D-printed.”

    Going for a quick glide

    While their AI pipeline seemed realistic, the researchers needed to ensure its predictions about glider performance were accurate by experimenting in more lifelike environments.

    They first fabricated their two-wing design as a scaled-down vehicle resembling a paper airplane. This glider was taken to MIT’s Wright Brothers Wind Tunnel, an indoor space with fans that simulate wind flow. Placed at different angles, the glider’s predicted lift-to-drag ratio was only about 5 percent higher on average than the ones recorded in the wind experiments — a small difference between simulation and reality.

    A digital evaluation involving a visual, more complex physics simulator also supported the notion that the AI pipeline made fairly accurate predictions about how the gliders would move. It visualized how these machines would descend in 3D.

    To truly evaluate these gliders in the real world, though, the team needed to see how their devices would fare underwater. They printed two designs that performed the best at specific points-of-attack for this test: a jet-like device at 9 degrees and the four-wing vehicle at 30 degrees.

    Both shapes were fabricated in a 3D printer as hollow shells with small holes that flood when fully submerged. This lightweight design makes the vehicle easier to handle outside of the water and requires less material to be fabricated. The researchers placed a tube-like device inside these shell coverings, which housed a range of hardware, including a pump to change the glider’s buoyancy, a mass shifter (a device that controls the machine’s angle-of-attack), and electronic components.

    Each design outperformed a handmade torpedo-shaped glider by moving more efficiently across a pool. With higher lift-to-drag ratios than their counterpart, both AI-driven machines exerted less energy, similar to the effortless ways marine animals navigate the oceans.

    As much as the project is an encouraging step forward for glider design, the researchers are looking to narrow the gap between simulation and real-world performance. They are also hoping to develop machines that can react to sudden changes in currents, making the gliders more adaptable to seas and oceans.

    Chen adds that the team is looking to explore new types of shapes, particularly thinner glider designs. They intend to make their framework faster, perhaps bolstering it with new features that enable more customization, maneuverability, or even the creation of miniature vehicles.

    Chen and Hagemann co-led research on this project with OpenAI researcher Pingchuan Ma SM ’23, PhD ’25. They authored the paper with Wei Wang, a University of Wisconsin at Madison assistant professor and recent CSAIL postdoc; John Romanishin ’12, SM ’18, PhD ’23; and two MIT professors and CSAIL members: lab director Daniela Rus and senior author Wojciech Matusik. Their work was supported, in part, by a Defense Advanced Research Projects Agency (DARPA) grant and the MIT-GIST Program.

    Continue Reading

  • Saudi Arabia to allow foreign property ownership in Riyadh and Jeddah – Middle East Eye

    1. Saudi Arabia to allow foreign property ownership in Riyadh and Jeddah  Middle East Eye
    2. Saudi Arabia to open property market to foreigners in 2026  Gulf News
    3. Al-Hogail Thanks the Leadership for the Council of Ministers’ Approval of the Updated Regulation for Non-Saudis’ Ownership of Real Estate  Yahoo Finance
    4. Saudi Arabia Enacts New Real Estate Foreign Ownership Law: A Calibrated Opening for Foreign Investors  The National Law Review
    5. Saudi foreign property ownership rules will be ‘transformational’ for long-term expats  thenationalnews.com

    Continue Reading

  • Warner Music, Concord & More

    Warner Music, Concord & More

    With three deals coming in at more than $1 billion, not even Taylor Swift’s masters purchase managed to crack the mid-year list.  

    What the biggest music industry deals of 2025 lacked in star power, they made up for in sheer size: The top five transactions announced in the first half of the year include three items over $1 billion, with the smallest coming in at $450 million. Notably, the list doesn’t include the starriest deal of the year so far: Taylor Swift’s purchase of her Big Machine master recordings. Swift’s reclamation of her first six albums attracted more media attention than any other music business deal so far this year, but with a smaller price tag than the top five, it’s left to vie for a spot on the year-ending top 10 (or more) list. 
     
    Last year, music companies made numerous noteworthy acquisitions, including Sony Music’s purchase of Queen’s catalog for $1.27 billion; Universal Music Group’s deals for [PIAS] and Downtown Music Holdings (which hasn’t closed and is being reviewed by the European Commission); Blackstone’s $1.6-billion acquisition of Hipgnosis Songs Fund; and New Mountain Capital’s purchase of BMI for between $1.3 billion and $1.5 billion. The live sector was also active, with Legends picking up ASM Global from AEG for $2.3 billion and KKR buying Superstruct for $1.39 billion.  
     
    Lacking super-sized catalog acquisitions, Billboard’s list of the largest deals announced in the first half of 2025 is instead dominated by fundraising to enable the purchase of music rights. Two of the five deals involve asset-backed securities (ABSs), a type of debt that allows an owner of large, diversified music catalogs to finance its borrowings with royalties from its catalogs and which has become increasingly common in the music business. Several companies have raised money through ABSs since 2022, including Concord, Kobalt, Hipgnosis Song Management, HarbourView Equity Partners, Chord Music Partners and Influence Media. 
     
    Other than Swift’s purchase of her masters, there were numerous other noteworthy catalog deals that fell short of making the top five. Sony Music Publishing acquired Hipgnosis Songs Group for an undisclosed amount that Billboard nonetheless believes is safely below the threshold to make this list. And in March, Create Music Group acquired the catalogs of deadmau5 and his label, mau5trap, followed in April by its purchase of indie electronic label !K7.  
     
    Check out the top five deals from the first half of 2025 below. 

    Continue Reading

  • First-trimester antibiotic use for urinary tract infections tied to more congenital malformations

    First-trimester antibiotic use for urinary tract infections tied to more congenital malformations

    A study of more than 70,000 US pregnancies suggests a commonly used antibiotic for urinary tract infections (UTIs) may be tied to increased risk of congenital malformations when taken during the first trimester of pregnancy.

    The study, published today in JAMA Network Open, found that exposure to trimethoprim-sulfamethoxazole (TMP-SMX) during the first trimester was associated with increased risk of any malformation, severe cardiac and other cardiac malformations, and cleft lip and palate compared with beta-lactam antibiotics. No increased risk of congenital malformations was observed with nitrofurantoin, which is also commonly used to treat UTIs.

    The study partly substantiates the concerns of the American College of Obstetricians and Gynecologists (ACOG), which has suggested that TMP-SMX and nitrofurantoin be avoided during the first trimester when possible because of uncertainty about the risk of congenital malformations, though studies to date have produced mixed results. Despite the ACOG recommendation, the two antibiotics still account for more than half of first-trimester UTI prescriptions, according to the study authors. 

    One of the more common infections during pregnancy

    For the study, a team of researchers from Vanderbilt University Medical Center, Washington University School of Medicine in St. Louis, and the University of Washington used the Merative MarketScan Commercial Database to identify a cohort of pregnant women who received first-trimester antibiotics (TMP-SMX, nitrofurantoin, fluoroquinolones, and beta-lactams) for uncomplicated UTIs and their live-born infants. 

    UTIs are one of the more common infections that occur during pregnancy, affecting roughly 8% of pregnancies.

    “Existing evidence on the risk of malformations associated with first-trimester antibiotic therapy for UTI is limited,” the researchers wrote. “To our knowledge, our study is the first large-scale examination restricted to pregnant individuals with UTI.”

    The primary outcome of the study was congenital malformations (any and by organ system) identified up to a year after birth. To assess associations with increased risk of congenital malformations, the study used beta-lactams as the active comparator because beta-lactams are widely accepted as safe during pregnancy.

    Higher risk of any malformation

    Of the 71,604 pregnancies that met the inclusion criteria, 42,402 (59.2%) had first-trimester exposure to nitrofurantoin, 3,494 (4.9%) to TMP-SMX, 3,663 (5.1%) to fluoroquinolones, and 22,045 (30.8%) to beta-lactams. The median age of pregnant individuals was 30, and patient characteristics were similar across agents. The median gestational age differed by antibiotic (nitrofurantoin, 62 days; TMP-SMX, 26 days; fluoroquinolones, 18 days; beta-lactams, 63 days).

    A total of 1,518 infants had malformations, including 729 with cardiac malformations. The unadjusted absolute risk of any malformation was 26.9 per 1,000 infants for TMP-SMX, 23.5/1,000 infants for fluoroquinolones, 21.2/1,000 infants for nitrofurantoin, and 19.8/1,000 infants for beta-lactams. 

    After adjustments were made for potential confounders—including demographic characteristics, comorbidities, concomitant medications, and measures of healthcare use—TMP-SMX-exposed pregnancies had a 35% higher risk of any malformation compared with those exposed to beta-lactams (risk ratio [RR], 1.35; 95% confidence interval [CI], 1.04 to 1.75). The number needed to harm was 1 additional malformation for every 145 TMP-SMX-exposed pregnancy. The risks for infants exposed to nitrofurantoin (RR, 1.12; 95% CI, 1.00 to 1.26) and fluoroquinolones (RR, 1.18; 95% CI, 0.87 to 1.60) were similar to those exposed to beta-lactams.

    In the analysis of organ-specific malformations, TMP-SMX was associated with increased risk of severe cardiac malformations (RR, 2.09; 95% CI, 1.09 to 3.99) and other cardiac malformations (RR, 1.52; 95% CI, 1.02 to 2.25) on a relative scale compared with beta-lactams. The risk of cleft lip and palate was more than triple (RR, 3.23; 95% CI, 1.44 to 7.22) among TMP-SMX-exposed pregnancies. 

    The results were generally consistent in sensitivity analyses.

    “Our results support the current ACOG recommendation for caution in using TMP-SMX during the first trimester but do not support current recommendations to limit nitrofurantoin use,” the authors concluded.

    Continue Reading

  • Global Study Warns of Rising PAH Burden

    Global Study Warns of Rising PAH Burden

    The global impact of pulmonary arterial hypertension (PAH) is not uniform, with 2021 data from the Global Burden of Disease (GBD) study showing wide variances in patient treatment and outcomes in connection with rates of age-standardized incidence (ASIR), mortality (ASMR), and disability-adjusted life-years (ASDR). Prevention, management, and health equity strategies to help alleviate this burden need to be better as a result, experts warn.

    New data published in Frontiers in Public Health1 show that globally, PAH cases rose 85.6% in the 32 years (1990-2021) leading up to the study, and they highlight the urgency of optimizing public health strategies to meet the needs of all stakeholders involved.

    “Despite notable advancements in diagnostic and therapeutic modalities in recent years,” the study authors wrote, “there remains a critical need for a deeper comprehension of the global disease burden of PAH to better understand its specific impact on public health.”

    The data are telling. In 1990, all-age cases of PAH totaled 23,301 (95% UI, 19,037-27,809), but by 2021, this had risen to 43,251 (95% UI, 34,705-52,441) cases. Per 100,000 population, the corresponding ASIR rose from 0.5 (95% UI, 0.4-0.6) to 0.52 (95% UI, 0.42-0.62). Further, there were similar trends in ASMR. From 1990 to 2021, global deaths from PAH rose from 14,842 (95% UI, 12,370-17,485) to 22,021 (95% UI, 18,239-25,352); however, there was a drop in ASMR for this, from 0.35 (95% UI, 0.29-0.42) to 0.27 (95% UI, 0.23-0.32). By 2021, there were 642,104 disability-adjusted life-years (DALYs) due to PAH, which broke down to 8.24 (95% UI, 7.14-9.39) per 100,000 population and an estimated annual percentage change (EAPC) of –1.31 (95% CI, –1.43 to –1.19).

    The present study authors note that although previous studies have attempted to do as they did, those analyses primarily focused on specific regions or countries. | Image Credit: Kiattisak-stock.adobe.com

    Disparities were evident when the authors considered socio-demographic index (SDI) at the regional level. For example, the greatest ASIR decrease—from 0.78 (95% UI, 0.64-0.93) to 0.71 (95% UI, 0.58-0.85) per 100,000, translating to EAPC of –0.03 (95% CI, −0.36% to −0.25%)—was seen in areas with the lowest SDI, while areas considered to have a high-middle SDI saw one of the highest increases: from an ASIR of 0.43 (95% UI, 0.35-0.52) to 0.46 (95% UI, 0.37-0.55), for an EAPC of 0.03 (95% CI, –0.05 to 0.12).

    For mortality, middle-SDI regions had the highest ASMR per 100,000, at 0.33 (95% UI, 0.22-0.39), whereas high-SDI regions had an ASMR of 0.22 (95% UI, 0.19-0.23). The ASDRs in regions with a higher SDI reflected these results: in high-middle SDI regions, the ASDR was 9.3 (95% UI, 6.08-13.2) compared with 6.16 (95% UI, 5.76-6.49) in high-SDI regions.

    Drilling down to more specific regions, sub-Saharan Africa demonstrated the highest incidence of PAH of 0.92 (95% UI, 0.75-1.09) per 100,000 population, while western sub-Saharan Africa had the greatest ASIR EAPC decline of –1.15 (95% UI, –1.27 to –1.02). However, between 1990 and 2021, the EAPC for ASMR from PAH rose the most in Central Asia (0.3; 95% UI, 0.06-0.53), while it decreased the most in Eastern Europe (–3.78; 95% UI, –4.18 to –3.37). Central Asia was the only region, the authors wrote, to demonstrate an increasing trend. In addition, the highest ASDRs were seen in North Africa and the Middle East (14.81 per 100,000; 95% UI, 10.76-17.95) and Central Asia (12.91 per 100,000; 95% UI, 10.61-15.60).

    The authors also looked at the impact of such influences as age and sex, and they saw that regions with a lower SDI had especially high incidence rates in children younger than 5 years whereas there were more cases in adults 50 years and older in high- and high-middle SDI regions. By 2021, the mortality rates overall had improved for children younger than 5, but not so for adults older than 65 years, for whom mortality rates increased in high SDI regions.

    Highlighting the power of their results, the present study authors note that although previous studies have attempted to quantify PAH trends, those analyses primarily focused on specific regions or countries.2,3 These, they caution, “may suffer from methodological limitations that compromise their precision,” while the GBD study’s approach “provides more comprehensive and accurate estimates of the disease burden.”

    Their wider-reaching investigation was able to better show the persistent threat of PAH, that it remains a significant public health concern, and that interventions to head off the impact of PAH need to be tailored on the preventive and therapeutic fronts to better meet population-specific needs.

    References

    1. Liu Z, Mo L, Cao W, et al. Global, regional, and national trends in pulmonary arterial hypertension burden, 1990–2021: findings from the global burden of disease study 2021. Front Public Health. 2025:13:1516365. doi:10.3389/fpubh.2025.1516365
    2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030. doi:10.1164/rccm.200510-1668OC
    3. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(suppl 25):D51-D59. doi:10.1016/j.jacc.2013.10.023

    Continue Reading

  • Internship Spotlight: Nina Chung ’26, Procter & Gamble

    Internship Spotlight: Nina Chung ’26, Procter & Gamble

    Internship company name and location: Procter & Gamble, Cincinnati, Ohio
    Hometown: Edison, New Jersey
    Pronouns: she/her/hers
    The SOM classes you’re using on the job: YCCI Discovery Projects, Customer, Executive, and Competitor
    Go-to work lunch: Currito
    After-work routine: Running or playing pickleball with fellow interns!
    Favorite thing about internship city: The sense of community—we’re always hanging out together and bump into each other at various events!

    Prior to Yale SOM, I worked as a software engineer, but I’ve always been drawn to consumer psychology and tangible products that people use every day. I hadn’t heard of brand management before coming to SOM, but when I learned about the internship opportunity at Procter & Gamble (P&G), I was immediately intrigued. What attracted me most was P&G’s culture of developing leaders; the opportunity to work at the intersection of functions including finance, marketing, media, analytics, and supply chain; and the chance to contribute to meaningful, high-impact projects from day one. Plus, I’d be working with iconic brands I’ve grown up with.

    When I received my internship offer, I knew I wanted to make the most of it, especially since I had no formal background in marketing. That’s why I joined the Yale Center for Customer Insights (YCCI) Discovery Projects: to build a foundation in real-world consumer insight work before my first day at P&G.

    Through the course, I worked with the Ladies’ Professional Golf Association (LPGA) on a project aimed at increasing viewership and attendance among Asian American audiences. We conducted online ethnography by digging into social media platforms, performed competitive patterning, interviewed consumers to uncover beliefs and goals, and tested creative hypotheses by developing ads and social posts ourselves. It was a crash course in insight generation, strategy, and storytelling.

    Those skills transferred directly into my summer on the Olay Body team at P&G, where I’m focused on understanding trends in body wash routines and how Olay can meet consumers’ evolving needs. I used the same toolkit I developed through YCCI: conducting online ethnography to analyze bath-related trends, identifying consumer sentiment around Olay and competitors, defining a clear target segment, and conducting interviews to learn more about people’s shower routines. I was even able to synthesize insights from past interviews conducted by my team, quickly spotting patterns and unmet market needs.

    As with the LPGA project, I sought inspiration from outside sources. In this case, I studied competitors in the bath and body space and what Olay could learn from their approaches. As the summer progressed, I applied frameworks from core courses Customer, Executive, and Competitor to shape a go-to-market plan that brings those insights to life.

    This internship has been so much more than just a summer project. I’ve been able to meet amazing peers from MBA programs across the country while sharpening my brand strategy skills and exploring Cincinnati, where the intern community is strong, social, and supportive.

    I’m incredibly grateful to the team at P&G, SOM, and YCCI for preparing me so well for this experience—and for making this summer so meaningful and fun.

    Continue Reading

  • Long-Term Remission, OS With Cilta-Cel Sets New Benchmark for Survival Outcomes in R/R Myeloma

    Long-Term Remission, OS With Cilta-Cel Sets New Benchmark for Survival Outcomes in R/R Myeloma

    Treatment with a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti) has demonstrated “quite remarkable” long-term remission and survival outcomes in heavily pretreated patients with relapsed/refractory multiple myeloma, indicating the curative potential of this agent, according to Peter Voorhees, MD.

    Five-year follow-up data from the phase 1b/2 CARTITUDE-1 trial (NCT03548207) were presented at the 2025 ASCO Annual Meeting, and showed that 33% of patients who received cilta-cel were treatment- and progression-free at 5 years or longer.1 Notably, patients enrolled onto the trial had previously received 3 or more lines of therapy.2

    “Now that we have a median follow-up that extends just beyond 5 years, the median overall survival [OS] in this group of patients is [60.7 months], which is really quite remarkable,” Voorhees emphasized during an interview with OncLive®. “In the LocoMMotion study [NCT04035226]…the median OS was 12.4 months [in patients with relapsed/refractory multiple myeloma treated with cilta-cel].3 To extend that out to 5 years [in CARTITUDE-1] is [significant], and is 5 times longer than we would have expected in this patient population.”

    In the interview, Voorhees discussed the background and rationale for evaluating the 5-year remission and survival after cilta-cel infusion, key efficacy and safety data from this analysis, and the clinical implications of these data for cilta-cel use in relapsed/refractory multiple myeloma.

    Voorhees is a member of the Hematology Department at Atrium Health Levine Cancer Institute and a professor of cancer medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.

    OncLive: What was the background and rationale for evaluating the long-term remission and survival rates following cilta-cel administration in heavily pretreated relapsed/refractory multiple myeloma?

    Voorhees: CARTITUDE-1 was a phase 1b/2, study that evaluated the safety and efficacy of the BCMA-targeted CAR T-cell therapy, cilta-cel, for patients with relapsed/refractory multiple myeloma. This was specifically for patients who were triple-class exposed, in other words, they’d been treated previously with CD38 antibodies, PIs, and IMiDs. They had to have had 3 or more prior lines of therapy, or less than that, if they were double refractory. As far as previous data from this study, the original publication demonstrated a 98% overall response rate [ORR]. Most of those responses were complete responses [CRs], and most of those CRs were minimal residual disease [MRD]–negative with longer follow-up.

    We established a median PFS from this study of nearly 3 years now. To put that into some perspective, the LocoMMotion study was a prospective registry trial that evaluated expected outcomes in the modern era in this similar group of patients who were triple class exposed to 3 or more prior lines of therapy. In that registry study, the median PFS was only 4.6 months. To achieve a median PFS of 36 months is really quite remarkable. With this long-term follow-up, what we really wanted to [identify] for those patients who are still responding was how durable those responses are, and what the median OS looks like at this time.

    What were the baseline patient characteristics?

    Regarding the baseline characteristics, patients had triple class–exposed multiple myeloma and had previous exposure to CD38 antibodies, PIs, and IMiDs. They had to have had 3 or more prior lines of therapy or be double refractory to an IMiD and a PI. This was a single-arm study. Patients [underwent] leukapheresis and then went on to receive cilta-cel infusion after 3 days of lymphodepleting chemotherapy with fludarabine and cyclophosphamide. For this long-term follow-up [analysis], patients on this particular CARTITUDE program segued into this CARTITUDE study to track durability of PFS, and, just as importantly, OS, and any long-term potential adverse effects [AEs] that we might see.

    What were the key efficacy findings?

    Ninety-seven patients were treated with cilta-cel in this particular study. Remarkably, at 5 years and beyond, 33% of those 97 patients are still alive and progression-free. In one of the centers that enrolled a particularly high number of patients, they were doing annual MRD assessments and PET/CTs on their patients who had achieved a stringent CR [sCR]. Of these 12 patients, all of them were MRD-negative at 5 years and beyond and in a complete metabolic response by PET/CT. This raises the question as to whether some of these patients may be cured after a single infusion of cilta-cel. Whether you want to use the word cure or not, everyone would be very comfortable in saying that these are unprecedented remissions.

    Was there anything to note about the safety profile of cilta-cel with the long-term follow-up?

    Fortunately, there were no new safety signals observed in this particular study with long-term follow-up. We observed no new cases of the movement and neurocognitive toxicities that had been seen previously [with cilta-cel]. This is a Parkinson-like AE that is of concern. We did not see any new cases of cranial nerve palsies or demyelinating polyneuropathies. There were no new cases of secondary hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia, or CAR T-cell lymphomas. There were 2 additional secondary primary malignancies seen: one adenocarcinoma of the lung and one squamous cell carcinoma of the anus. [These] were felt not to be cilta-cel–related. There were several higher-grade infections that were seen, [although] none were attributed to cilta-cel.

    What are the implications of these data for the use of cilta-cel clinical practice?

    The data speak for themselves as far as achieving an unprecedented durability of remission in this patient population. What was exciting about this study was that, from a correlative perspective, when we evaluated the CAR T-cell [therapy] itself, there was an increased proportion of naive T cells in the product of the patients who had more durable remissions. When we [assessed this] post–cilta-cel infusion, [there was] a higher effector-to-target ratio; this was associated with better outcomes. Interestingly, the expansion of central memory T cells looks to be associated with these longer remissions, which does seem to make some biologic sense. That’s exciting because we would imagine and expect that the T cell fitness of patients who have been less heavily pretreated is going to be better [than those who were heavily pretreated.] Not only that, but we can more effectively control the effector-to-target ratio, and we can [decrease] the burden of target with more effective therapy in earlier lines of therapy.

    [Overall,] the initial data from the CARTITUDE-4 study [NCT04181827], a randomized study that evaluated cilta-cel vs the standard of care for patients who had 1 to 3 prior lines of therapy, [showed] remarkable PFS curves, particularly in the standard-risk patient population. Also, CARTITUDE-5 [NCT04923893] and CARTITUDE-6 [NCT05257083] are randomized phase 3 studies investigating cilta-cel in newly diagnosed patients who are either transplant ineligible or eligible, respectively. We’ll see if we’re achieving long-term remissions and possibly more cures when we’re using cilta-cel.

    References

    1. Jagannath S, Martin TG, Lin Y, et al. Long-term (≥5-year) remission and survival after treatment with ciltacelcabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. Published online June 3, 2025. doi: 10.1200/JCO-25-00760
    2. Carvykti is the first and only BCMA-targeted treatment approved by the U.S. FDA for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. News release. Johnson & Johnson. Updated April 6, 2025. Accessed July 9, 2025. https://www.jnj.com/media-center/press-releases/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy

    Continue Reading

  • ‘It’s been an honour’ – Christian Horner bids farewell to Red Bull in emotional social media post

    ‘It’s been an honour’ – Christian Horner bids farewell to Red Bull in emotional social media post

    Christian Horner has shared his first public comments after being replaced as Red Bull Racing’s CEO and Team Principal, saying he leaves the operation “with a heavy heart” but “immense pride” over their Formula 1 journey and achievements.

    A former racing driver and Formula 3000 team boss, Horner was given the chance to lead Red Bull into their first F1 season back in 2005 – becoming the sport’s youngest team boss at just 31 years of age.

    Making key hires across the board, Horner oversaw Red Bull’s rise from points scorers to World Champions, with their tallies now standing at a whopping 107 pole positions, 124 race wins, 287 podiums, six Teams’ Championships and eight Drivers’ Championships.

    Following Wednesday’s announcement of a managerial reshuffle, which sees Racing Bulls Team Principal Laurent Mekies take over as Red Bull’s new chief, and Alan Permane slot into the Frenchman’s former role, Horner took to social media to share his thoughts.

    “After an incredible journey of 20 years together, it is with a heavy heart that today I say goodbye to the team I have absolutely loved,” read Horner’s message, which followed tributes from current Red Bull drivers Max Verstappen and Yuki Tsunoda.

    “Every one of you, the amazing people at the factory, have been the heart and soul of everything that we have achieved. Win and lose, every step of the way, we have stood by each other as one and I will never forget that.

    “It’s been a privilege being part of and leading this epic team and I am so proud of our collective accomplishments and you all.

    “Thanks to the amazing partners and fans who enabled us to go racing. Your support has helped grow the team from its humble beginnings to an F1 powerhouse that laid claim to six Constructors’ Championships and eight Drivers’ Championships.

    “Equally, thank you to our rivals, with[out] whom there would be no racing at all. You’ve pushed us, challenged us, and enabled us to achieve accolades we never dreamed possible. The competition has made every victory sweeter and every setback an opportunity to develop and grow.

    “Formula 1 is a sport built on relentless ambition, passion, and respect. The rivalries have been fierce, but the mutual drive to innovate and raise the bar is what has made this journey so special.

    “It’s been an honour to be part of this incredible era of motorsport. I leave with immense pride in what we’ve achieved and also with what’s in the pipeline for 2026 – and huge respect for everyone who’s made F1 the pinnacle it is today.”

    Continue Reading

  • Measles cases in U.S. hit highest level in over 30 years-Xinhua

    LOS ANGELES, July 9 (Xinhua) — The number of measles cases in the United States has hit the highest level in more than 30 years, according to the data released Wednesday by the U.S. Centers for Disease Control and Prevention (CDC).

    A total of 1,288 measles cases have been confirmed in the country, with 13 percent of cases hospitalized, so far in 2025, making it the worst year since 1992, when 2,126 cases were confirmed.

    The cases were reported across 38 states nationwide, with 753 in Texas alone, according to the CDC.

    There have been 27 outbreaks reported in 2025, and 88 percent of confirmed cases are outbreak-associated, said the CDC, adding that 92 percent of these cases are either unvaccinated or have an unknown vaccination status.

    The airborne, extremely infectious and potentially severe rash illness was officially eliminated from the United States in 2000, meaning there are no measles spreading within the country and new cases are only found when someone contracts measles abroad and returns to the country, the CDC explains on its website.

    Before the measles vaccine was introduced, an estimated 48,000 people were hospitalized and 400 to 500 people died in the United States each year.

    Continue Reading